Playing Russian Roulette With Tyrosine Kinase Inhibitors | Zendy

Szmulewitz R Z | Zendy; Ratain M J | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Playing Russian Roulette With Tyrosine Kinase Inhibitors

Author(s) -

Szmulewitz R Z,

Ratain M J

Publication year - 2013

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2012.245

Subject(s) - clinical pharmacology , formulary , dosing , medicine , pharmacology , food and drug administration , therapeutic window , drug , bioavailability , tyrosine kinase , tyrosine kinase inhibitor , intensive care medicine , cancer , receptor

With the advent of molecularly “targeted therapies,” most notably the tyrosine kinase inhibitors (TKIs), there has been a significant shift in our formulary from intravenous to orally administered medications. The effect of food on bioavailability is a significant consideration for many drugs, especially those with a narrow therapeutic window. This article focuses on the complicated issue of oncology drug dosing with respect to food, highlighting the impact of food labeling on patient safety. Clinical Pharmacology & Therapeutics (2013); 93 3, 242–244. doi: 10.1038/clpt.2012.245

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research